Capital Health acquires tech for
EDMONTON – PerkinElmer, Inc., of
Waltham, Mass., has announced a multi-year, multi-million dollar
agreement with Capital Health in Edmonton, Alberta, that provides
instruments, reagents, software and screening expertise to enhance the
region’s neonatal screening program.
The expanded program, which now includes screening for 17 metabolic
conditions in newborns, began province-wide on April 1, 2007.
Under the terms of the agreement, signed in the second half of 2006,
Capital Health has purchased tandem mass spectrometry systems, reagent
kits and PerkinElmer’s industry-leading Specimen Gate screening software
to expand Alberta’s newborn screening for inherited metabolic disorders
(IMDs),including cystic fibrosis.
Alberta is the first province in Canada to screen all newborns for
“We are pleased to partner with Capital Health to support its
state-of-the-art newborn screening program,” said Robert F. Friel,
president of PerkinElmer Life and Analytical Sciences. “PerkinElmer’s
technology is designed to allow these early detection programs to
identify infants at risk for devastating metabolic disorders, enabling
early intervention and treatment to save lives and improve quality of
Capital Health’s Laboratory at the University of Alberta Hospital
provides neonatal screening services for approximately 42,000 babies
born in Alberta annually. Capital Health is one of the largest academic
health regions in Canada.